CAMBRIDGE, MA, September 9, 2016 -- The CEO of Aurora BioPharma, Robert Brooks, will attend OktoberINVESTfest, the 5th Annual Investors Conference to be held once again at The New York Academy of Sciences, World Trade Center 7, on September 28, 2016. The building is one of New York's LEED- certified green buildings, representative of Bavaria's Energy Turn Around initiatives. This year's program will feature distinguished panelists and speakers complimented by power networking at the "Unconference Luncheon".
Aurora BioPharma is a biotechnology company, revolutionizing the way we will treat cancer in the future. After 50 years of surgery, radiation and chemotherapy, cancer rates are still expected to double in the next 15 years. Medicine has a new weapon, genetically reprogramming the immune system into an elite killer army. Already three companies involved in genetically engineered Chimeric Antigen Receptor (CAR) T therapy, have been awarded Breakthrough Therapy Designation by the FDA for showing up to 90% remissions or nearly a "cure" in leukemia and other liquid tumors. Aurora has shown in a human Phase I/II trial with Glioblastoma, the most lethal brain cancer, nearly double the survival of a $1 Billion drug without the side effects. Glioblastoma claimed the lives of Senator Ted Kennedy and Vice President Biden's son, and many others.
Our 5th Annual Investors conference, the OktoberINVESTfest aims to foster innovation and transatlantic investment by enabling financiers to learn about selected high quality American and German unique investment opportunities, both public and private in the sectors of life science and IT. This high energy event is hosted by Invest in Bavaria, the investment promotion agency of Germany's largest, most innovative state, Bavaria with capital city Munich. Munich, as rated by the European Commission, is Europe's #1 tech hub! Bavaria is a premier region in Europe for medical devices and biotech.
Aurora BioPharma, Inc.
Tel: (617) 674-7718 - Fax: (617) 674-7701
SOURCE Aurora BioPharma, Inc.